Skip to main content
. 2022 Sep 4;13(2):503–519. doi: 10.1007/s13346-022-01226-2

Fig. 9.

Fig. 9

Recurrence free survival (RFS) as a proportion of high-risk non-muscle invasive bladder cancer (NMIBC) subjects in the escalation cohorts 1–3 (n = 10; dotted line) vs. the high dose and expansion cohorts (solid line). Median RFS in the low dose escalation cohorts = 5.4 months vs. 12.2 months in the high-dose and expansion cohorts. Significance (*p < 0.05) determined using Log-rank Mantel-Cox test; hazard ratio (Mantel–Haenszel) = 0.29 with 95% CI = 0.09–0.88. Adapted with permission from [12]